X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (65) 65
index medicus (59) 59
genotype (36) 36
male (35) 35
female (34) 34
hepacivirus - genetics (33) 33
hepatitis (31) 31
antiviral agents - therapeutic use (29) 29
virology (28) 28
adult (27) 27
middle aged (25) 25
hepatitis c virus (24) 24
mutation (24) 24
hepatitis c (23) 23
ribavirin (22) 22
gastroenterology & hepatology (21) 21
genotype & phenotype (21) 21
hepatitis c, chronic - drug therapy (21) 21
sofosbuvir (20) 20
aged (19) 19
drug therapy, combination (19) 19
infectious diseases (19) 19
microbiology (19) 19
treatment outcome (19) 19
abridged index medicus (18) 18
replication (17) 17
patients (16) 16
viruses (16) 16
drug resistance, viral - genetics (15) 15
therapy (15) 15
uridine monophosphate - analogs & derivatives (15) 15
genotypes (14) 14
hepatitis c - drug therapy (14) 14
hepatitis c, chronic - virology (14) 14
resistance (14) 14
uridine monophosphate - therapeutic use (14) 14
antiviral agents (13) 13
antiviral agents - administration & dosage (13) 13
antiviral agents - adverse effects (13) 13
cirrhosis (13) 13
drug resistance (13) 13
drug therapy (13) 13
gastroenterology and hepatology (13) 13
hcv (13) 13
hepatitis-c virus (13) 13
infections (13) 13
ribavirin - therapeutic use (13) 13
cell line (12) 12
drug resistance, viral (12) 12
hiv-1 - genetics (12) 12
pharmacology & pharmacy (12) 12
viral load (12) 12
viral nonstructural proteins - genetics (12) 12
chemistry (11) 11
direct-acting antivirals (11) 11
health aspects (11) 11
hepacivirus - drug effects (11) 11
hepatitis c - virology (11) 11
immunology (11) 11
infection (11) 11
metallurgy (11) 11
organic chemistry (11) 11
sofosbuvir - therapeutic use (11) 11
sustained virologic response (11) 11
benzimidazoles - therapeutic use (10) 10
care and treatment (10) 10
clinical trials (10) 10
dna (10) 10
fluorenes - therapeutic use (10) 10
genetic aspects (10) 10
hiv infections - drug therapy (10) 10
hiv-1 - drug effects (10) 10
interferon (10) 10
sofosbuvir - administration & dosage (10) 10
treatment-naive patients (10) 10
viral nonstructural proteins - antagonists & inhibitors (10) 10
antiretroviral drugs (9) 9
human immunodeficiency virus--hiv (9) 9
human-immunodeficiency-virus (9) 9
variants (9) 9
analysis (8) 8
animals (8) 8
combination (8) 8
high-throughput nucleotide sequencing (8) 8
liver (8) 8
medicine, general & internal (8) 8
molecular sequence data (8) 8
phase-2 trial (8) 8
ribavirin - adverse effects (8) 8
tenofovir (8) 8
uridine monophosphate - adverse effects (8) 8
velpatasvir (8) 8
young adult (8) 8
acyclic or carbocyclic compounds (7) 7
adenine - analogs & derivatives (7) 7
adolescent (7) 7
efficacy (7) 7
genotype 1 (7) 7
hepacivirus - classification (7) 7
hepacivirus - isolation & purification (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 34 - 44
In this small, preliminary study of sofosbuvir, a nucleotide inhibitor of HCV polymerase, treatment with sofosbuvir and ribavirin, without peginterferon, was... 
GENOTYPE 1 | PSI-7977 | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | THERAPY | REPLICATION | RESISTANCE | REPLICON RNA-SYNTHESIS | COMBINATION | TREATMENT-NAIVE PATIENTS | PROTEASE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Adult | Female | RNA, Viral - metabolism | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hemoglobins - metabolism | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Drugs | Dose-response relationship (Biochemistry) | Antiviral agents | Usage | Patient outcomes | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Interferon | Infections | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1098 - 1106
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1993 - 2001
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1879 - 1888
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 27, pp. 2599 - 2607
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
In two trials involving patients with hepatitis C in whom previous treatment with direct-acting antiviral agents failed, treatment for 12 weeks with... 
GENOTYPE 1 | MEDICINE, GENERAL & INTERNAL | THERAPY | HEPATITIS-C VIRUS | EFFICACY | PROTEASE INHIBITOR GS-9857 | RESISTANCE | DIRECT-ACTING ANTIVIRALS | OPEN-LABEL | COMBINATION | PHASE-2 TRIAL | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals | Life Sciences | Human health and pathology
Journal Article